| Literature DB >> 35185113 |
Jake P Mann1, Benjamin Jenkins2, Samuel Furse2, Stuart G Snowden2,3, Anna Alisi4, Laura G Draijer5, Kylie Karnebeek6, Deirdre A Kelly7, Bart G Koot5, Antonella Mosca8, Camilla Salvestrini9, Indra van Mourik7, Anita Vreugdenhil6, Matthias Zilbauer9,10, Albert Koulman2.
Abstract
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition in children characterised by insulin resistance and altered lipid metabolism. Affected patients are at increased risk of cardiovascular disease (CVD) and children with NAFLD are likely to be at risk of premature cardiac events. Evaluation of the plasma lipid profile of children with NAFLD offers the opportunity to investigate these perturbations and understand how closely they mimic the changes seen in adults with cardiometabolic disease.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35185113 PMCID: PMC7613028 DOI: 10.1097/MPG.0000000000003418
Source DB: PubMed Journal: J Pediatr Gastroenterol Nutr ISSN: 0277-2116 Impact factor: 3.288
Figure 1Associations between baseline characteristics and NAFLD Activity Score in children biopsied for NAFLD (n=122).
Age (A) and homeostatic model of insulin resistance (HOMA-IR, C) were positively associated with NAFLD Activity Score, whilst serum alanine aminotransferase (C) was negatively associated. Body mass index (BMI, B) z-score, aspartate aminotransferase (D) and total serum triglycerides (E) were not associated with NAFLD Activity Score. Associations were tested using linear regression. q-values were derived using the Benjamini-Hochberg method where significance is q<.05.
Figure 2Associations between plasma lipid concentrations (μM) and fatty liver.
(A) Total phosphatidylcholines (PC) by cohort. (B) Association between PC(30:0) and alanine aminotransferase (ALT) in obese cohort. (C) Association between PC(38:5) and NAFLD Activity Score. (D) Heatmap of all lipids (rows) associated with traits (columns) within either the obese (blue) or NAFLD (pink) groups using linear regression adjusted for age and sex. The cell color represents the beta regression coefficient for each analysis and stars illustrate p-values. Cer, ceramide; GB-, Globoside; GD-/GM-, Ganglioside; Lac-Cer, Lactosylceramide; LPC, lysophosphatidylcholine; (L)PI, (lyso-)phosphatidylinositol; SM, sphingomyelin; S-, sphingosine; TG, triglyceride.
Figure 3Associations between plasma triglyceride concentrations (μM) and fatty liver.
(A) Total triglycerides (TG) by NAFLD Activity Score. (B) Association between TG(52:1) and hepatic fat fraction in obese cohort. (C) Association between TG(58:9) and NAFLD Activity Score. Associations were tested using linear regression adjusted for age and sex. (D) Summary of main lipid pathway perturbations.
Summary table of top lipids associated with histological severity of NAFLD with children.
Lipids were included if: significantly associated with NAFLD Activity Score in children and showed a directionally consistent association with hepatic steatosis on ultrasound in an independent cohort of adults. Some lipids were significantly associated with disease outcomes in adults: (+) indicates a positive / (-) negative association between plasma lipid levels and trait. Five lipids have genome-wide significant loci and these variants are also independently associated with cardiometabolic traits on phenome-wide association studies. ALP, alkaline phosphatase; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; LysoPC, lyso-phosphatidylcholine; PC, phosphatidylcholine; TG, triglyceride.
| Lipid | Association with NAS in children (current study) | Association with steatosis in adults (from Mann et al. 2020) | Associated disease outcomes in adults (from Pietzner et al. 2021) | GWAS-significant variants in or near genes | Cardiometabolic traits identified from PheWAS | ||
|---|---|---|---|---|---|---|---|
| Beta | p-value | Beta | p-value | ||||
| LysoPC 16:0 | 0.20 | 1.1E-03 | 0.06 | 1.7E-05 | Breast cancer (+), glaucoma (+), non-malignant skin cancer (+) | LIPC, MAF, MFSD2A | IHD, Death from PVD/mesenteric ischaemia/SAH, Metabolic syndrome |
| PC 36:4 | -0.23 | 1.5E-04 | -0.12 | 8.8E-03 | Colon cancer (-), death (-), endometrial carcinoma (-), cardiac failure (-), diabetes mellitus (-), asthma (-), COPD (-), venous thromboembolism (-) | FADS1-2-3, FADS2 | Death from CVD, Serum ALP, Arterial thrombosis, HbA1c, Fasting glucose, Metabolic syndrome, Colorectal cancer, Limb fat |
| PC 37:4 | -0.19 | 9.4E-04 | -0.21 | 1.2E-06 | FADS2 | Death from CVD, Serum ALP, Arterial thrombosis, HbA1c, Fasting glucose, Metabolic syndrome, Colorectal cancer, Limb fat | |
| PC 38:3 | -0.19 | 1.0E-03 | -0.27 | 1.2E-09 | FADS1-2-3 | HbA1c, Fasting glucose, Metabolic syndrome, Colorectal cancer, Limb fat | |
| PC 38:5 | -0.29 | 2.5E-07 | -0.22 | 1.4E-06 | Death (-), asthma (-) | FADS2 | Death from CVD, Serum ALP, Arterial thrombosis, HbA1c, Fasting glucose, Metabolic syndrome, Colorectal cancer, Limb fat |
| PC 38:6 | -0.29 | 4.5E-07 | -0.06 | 3.3E-06 | Death (-), cardiac failure (-), peripheral arterial disease (-), asthma (-), COPD (-) | ||
| PC 40:2 | -0.19 | 2.0E-03 | -0.31 | 6.2E-12 | |||
| PC 40:7 | -0.29 | 5.8E-07 | -0.23 | 3.8E-07 | Breast cancer (-), death (-), diabete mellitus (-), asthma (-), COPD (-), lung cancer(-) | ||
| TG 58:9 | -0.24 | 4.3E-05 | -0.09 | 4.2E-02 | |||